Abstract
Objective: The objective of this study was to investigate the roles and mechanisms of inflammatory mediators NLRP3 and IL-1β in refractory temporal epilepsy brain injury.Method: First, the brain tissue and the peripheral blood of children undergoing intractable temporal lobe epilepsy surgery were analyzed as research objects. The expression levels of NLRP3 in brain tissue and IL-1β in blood were measured. A model of temporal lobe epilepsy was established using wild-type and NLRP3 knockout 129 mice. Pilocarpine was injected intraperitoneally into the experimental group, and isovolumetric saline was injected intraperitoneally into the control group (n = 8 in each group). The expression of IL-1β in the peripheral blood, cerebral cortex, and hippocampus of mice was measured by ELISA at 3 h, 24 h, 3 days, and 7 days after modeling. Fluoro-Jade B (FJB) and TUNEL methods were used to determine necrosis and apoptosis in hippocampal neurons, respectively, and the expression of NLRP3 in the cortex was measured by immunofluorescence methods.Result: (1) The IL-1β levels in the peripheral blood of children with intractable temporal lobe epilepsy were higher than those in the control group (t = 2.813, P = 0.01). There was also a positive correlation between IL-1β expression levels and the onset time of a single convulsion in patients with refractory epilepsy (r = 0.9735, P < 0.05). The expression level of NLRP3 in the cerebral cortex of patients with refractory temporal lobe epilepsy was higher than that in the control group. (2) The expression level of NLRP3 in the hippocampus of wild-type mice increased 3 days after modeling and decreased slightly at 7 days but remained higher than that of the control group. IL-1β levels in peripheral blood were significantly higher than those in the control group at 3 days (t = 8.259, P < 0.0001). The IL-1β levels in the peripheral blood of NLRP3 knockout mice were lower than those in the wild-type group at 3 days (t = 3.481, P = 0.004). At day 7, the neuronal necrosis and apoptosis levels in the CA3 region of the hippocampus decreased.Conclusion: NLRP3 may be involved in the development of refractory temporal lobe epilepsy. Inhibiting NLRP3 may alleviate local brain injury by downregulating the IL-1β expression. The IL-1β levels in the peripheral blood of patients with refractory temporal lobe epilepsy may reflect the severity of convulsions.
Highlights
Refractory epilepsy (RE) refers to epilepsy in which patients still have seizures after being treated with two kinds of antiepileptic drugs that are correctly selected and can be tolerated
It was previously observed that the expression levels of inflammatory factors, such as IL-1β and IL-18 were increased in the serum of epilepsy patients during the interseizure period and that the levels of IL-17A and IFN-γ in the plasma of epileptic patients with different seizure types reflected the severity of epilepsy [16,17,18]
Dubé et al found that inflammatory cytokines played a crucial role in epilepsy caused by febrile seizures in children [19]
Summary
Refractory epilepsy (RE) refers to epilepsy in which patients still have seizures after being treated with two kinds of antiepileptic drugs that are correctly selected and can be tolerated. RE can induce permanent brain damage, especially neuronal death within the hippocampus [1]. Repeated seizures promote inflammatory reactions, which induce free radical production, neuronal metabolism overload, and increased excitatory glutamate. Increased glutamate levels can potentially injure neurons and further aggravate seizures [5]. Some investigators have observed increased levels of peripheral neutrophils, plasma albumin, and the inflammatory factor IL-1β in patients with recurrent seizures [6]. The anti-inflammatory drug dexmedetomidine can downregulate IL-1β expression and that of other inflammatory mediators to reduce seizures and brain damage in epileptic mice. FK506 ameliorated the course of pilocarpine-induced epilepsy and the neuronal loss in the rat hippocampus after SE [7, 8]. The regulatory mechanism of inflammatory mediators in RE patients is still unclear
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.